Scinnohub Pharmaceutical Co. Ltd. has divulged cyclin-dependent kinase (CDK) inhibitors, particularly CDK9 inhibitors, reported to be useful for the treatment of cancer.
Scientists at Helmholtz Zentrum fur Infektionsforschung GmbH and Lead Discovery Center GmbH have identified α-hemolysin (Staphylococcus aureus) inhibitors reported to be useful for the treatment of staphylococcal pneumonia.
Scientists at Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Haisco Pharmaceutical Group Co. Ltd. has disclosed integrin αvβ1 and/or integrin αvβ6 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Chicken ovalbumin upstream promoter transcription factor 2 (COUP-TFII, aka NR2F2) is dysregulated in different cancer types. However, its exact role remains controversial because it acts as an oncosuppressor in some tumors and as an oncogene in others. In glioma progression, the role of COUP-TFII is still unclear.
Researchers from the University of Miami and Harvard Medical School have published data from a study that assessed the role of recessive variants in the HBS1L gene, which encodes for HBS1-like translational GTPase crucial for ribosomal rescue, in inherited retinal disease.
Artelo Biosciences Inc.’s IND application for ART-26.12, for the treatment of chemotherapy-induced peripheral neuropathy, has been granted clearance by the FDA allowing the company to initiate a first-in-human phase I study. Results are expected in the first half of next year.
The targeted delivery of radionucleotides into tumors, known as radioimmunotherapy (RIT), has proven effective mainly in hematological cancer treatment, but its usefulness in solid tumors needs further exploration. Researchers from Oncoone Research & Development GmbH described the use of Pretarg-it, a novel pre-targeted RIT strategy that consists of ON-105 and the radioactively labeled DOTA-di-HSG peptide.
Scinai Immunotherapeutics Ltd. has reported successful in vivo preclinical study results for its anti-IL-17A/F VHH antibody fragment (NanoAb) as a local intralesional biological treatment for mild to moderate plaque psoriasis. The NanoAb targets the two isoforms of the cytokine IL-17 (A and F) implicated in plaque psoriasis.
RSS
